An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib

Radiother Oncol. 2020 Nov:152:96-100. doi: 10.1016/j.radonc.2020.07.051. Epub 2020 Jul 31.

Abstract

Our study is the first to report an especially high rate of grade 2 or worse radiation pneumonitis in patients treated with thoracic radiotherapy and simultaneous Osimertinib, despite total lung V5, V20 and MLD seeming unlikely to induce radiation pneumonitis.

Keywords: Osimertinib; Radiation pneumonitis; Thoracic radiotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acrylamides
  • Aniline Compounds
  • Carcinoma, Non-Small-Cell Lung*
  • Humans
  • Lung
  • Lung Neoplasms* / therapy
  • Radiation Pneumonitis* / epidemiology
  • Radiation Pneumonitis* / etiology
  • Radiotherapy Dosage

Substances

  • Acrylamides
  • Aniline Compounds
  • osimertinib